BioSpace News Archive

Antengene Corporation Limited (“Antengene” SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for hematology and oncology, recently announced its interim results for the six months ended June 30, 2022.

Erin Ambrose knew the day would come. The day she would once again watch her daughter, Hailey, be wheeled into an operating room so that a team of cardiac specialists could repair her heart.

Scilex Holding Company, a commercial biopharmaceutical company focused on developing and commercializing non-opioid therapies for patients with acute and chronic pain, announced that FDA has granted fast track designation for its investigational drug and device product candidate, SP-103.

Azenta, Inc. (Nasdaq: AZTA) today announced that Company management will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York City, on Tuesday, September 13, 2022, which includes a presentation beginning at 4:40 pm ET.

Merck, known as MSD outside the United States and Canada, issued its 2021/2022 Environmental, Social and Governance Progress Report.

Shuttle Pharmaceuticals Holdings, Inc., a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy while reducing side effects, announced the pricing of its initial public offering of 1,225,888 units of common stock and warrants, which priced at $8.125 per unit, raising gross proceeds of $9,960,340.

Advancements in oncology settings are improving patient quality of life. Due to effective biosimilars, healthcare providers are able to receive better outcomes in several cancer patients who can opt for convenient treatments such as a painless injections rather than receiving a lengthy chemotherapy session.

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe and Chief Financial Officer Jason Meggs are scheduled to present at the 2022 Baird Global Healthcare Conference on September 13, 2022, at 2:00 p.m. ET.

Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that Sean Brynjelsen, Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference.

Quince Therapeutics, Inc. (Nasdaq: QNCX), today presented preclinical data at the 14th International Conference on Osteogenesis Imperfecta (OI 2022) demonstrating the potential of its novel targeted therapeutic NOV004 to treat fracture in osteogenesis imperfecta (OI) by promoting accelerated increases in bone density, strength, and healing directly at the site of bone fracture.